Try searching for...
Dr Gonzalo Tapia-Rico
MBBS, PhD, FRACP
SA GenesisCare Clinical Research Lead
For patients/carers
For doctors
MBBS, PhD, FRACP
SA GenesisCare Clinical Research Lead
Locations
Clinical interests
- Gastrointestinal cancer
- Genitourinary cancer
- Skin cancer
- Lung cancer
Treatment techniques
- Chemotherapy
- Targeted therapy
- Hormone therapy
- Immunotherapy
Languages
Fluent
- English
- Spanish / Español
Biography
Clinical interest in lung, skin, gastrointestinal, and genitourinary cancers.
Dr Gonzalo Tapia Rico completed his medical degree at the Complutense University of Madrid in 2007 and his specialist training in Medical Oncology at Gregorio Marañón University Hospital, one of Spain’s leading hospitals, in 2012. In 2013, he was awarded a PhD for research into molecular subtypes of breast cancer.
Dr Tapia Rico subsequently worked as a Medical Oncologist in the United Kingdom at the Royal Infirmary and Western General Hospital in Edinburgh, and Addenbrooke’s Hospital in Cambridge. After moving to Australia in 2016, he worked at both The Queen Elizabeth Hospital and the Royal Adelaide Hospital.
Dr Tapia Rico has a strong interest in education, clinical trials, and research. He is a Clinical Senior Lecturer at the University of Adelaide and has published numerous peer-reviewed articles in leading oncology journals. He is a Fellow of the Royal Australasian College of Physicians (FRACP), serves on the RACP Overseas-Trained Physicians Subcommittee, which evaluates the comparability of international specialists seeking to practise in Australia, and is a member of several Australian and international cancer research groups.
His clinical practice covers a broad range of solid tumour malignancies, with particular interests in skin, gastrointestinal, and genitourinary cancers.
More information
- Royal Australasian College of Physicians (RACP)
- Fellow of the Royal Australasian College of Physicians (FRACP)
- Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., Yeo, E. C. F., Wittwer, N. L., Tapia Rico, G., Logan, J., Sivaloganathan, P., Collis, M., Ruszkiewicz, A., & Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659. https://doi.org/10.1136/jitc-2023-008659
- Boniface, D., & Tapia Rico, G. (2022). Oncology during the COVID-19 pandemic: A lockdown perspective. Current Oncology Reports, 24(10), 1219–1235. https://doi.org/10.1007/s11912-022-01301-4
- Mikaeel, R. R., Young, J. P., Tapia Rico, G., Hewett, P. J., Hardingham, J. E., Uylaki, W., Horsnell, M., & Price, T. J. (2021). Immunohistochemistry features and molecular pathology of appendiceal neoplasms. Critical Reviews in Clinical Laboratory Sciences, 58(6), 369–384. https://doi.org/10.1080/10408363.2021.1881756
- Tapia Rico, G., Yong, C. H., & Herrera Gómez, R. G. (2021). Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence? Critical Reviews in Oncology/Hematology, 167, 103503. https://doi.org/10.1016/j.critrevonc.2021.103503
- Chan, M. M., & Tapia Rico, G. (2019). The "pet effect" in cancer patients: Risks and benefits of human-pet interaction. Critical Reviews in Oncology/Hematology, 143, 56–61. https://doi.org/10.1016/j.critrevonc.2019.08.004
- Tapia Rico, G., Townsend, A. R., Broadbridge, V., & Price, T. J. (2017). Targeted therapies in elderly patients with metastatic colorectal cancer: A review of the evidence. Drugs & Aging, 34(3), 173–189. https://doi.org/10.1007/s40266-017-0439-9
- Tapia Rico, G., Chan, M. M., & Loo, K. F. (2020). The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews, 86, 102011. https://doi.org/10.1016/j.ctrv.2020.102011
